Panacea Biotec, a leading global biopharmaceutical company, is thrilled to announce a new milestone in its mission to protect children from life-threatening diseases. The U.S. International Development Finance Corporation (DFC) has committed $20 million as a long-term loan to Panacea Biotec, aimed at scaling up the manufacturing of the EasySix® vaccine, the world’s first fully-liquid hexavalent vaccine containing wP-IPV.

This investment will enable Panacea Biotec to expand its manufacturing capacity for drug substance antigens used in the EasySix® vaccine, positioning the company to meet the growing demand from U.N. agencies and public health organizations globally.

Nisha Biswal, Deputy CEO of DFC, highlighted the importance of this collaboration:
"Our partnership with India is both local and global. DFC is working to deliver concrete developmental impact for communities across India, and we are partnering with the Indian private sector to tackle some of the world’s most pressing challenges.”

Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec, expressed his enthusiasm for the partnership:
"We are excited to have DFC as our partner in our mission to protect children from critical diseases by providing innovative and affordable vaccines across the globe. Our hexavalent vaccine EasySix®, which meets the highest standards of safety and efficacy, will have a meaningful impact on the lives of millions of newborns in the developing world."

The EasySix® vaccine offers broad protection against six serious diseases—diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, and Haemophilus influenzae type B (Hib)—in a single, fully-liquid shot, making it an efficient and cost-effective solution for immunization programs worldwide. Panacea Biotec’s expanded manufacturing capacity will ensure reliable access to this life-saving vaccine, contributing to global efforts to reduce childhood mortality from preventable diseases.

This partnership exemplifies how public and private sector collaboration can address global health challenges, fostering positive outcomes for underserved communities, particularly in the developing world.